Search research articles
Contact Us
Filters
Showing results (11-20 of 192) with videos related to
Page
of 20
Sort By:
AIDS Research and Human Retroviruses
|
October 13, 2005
Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol
Elisabetta Bulgheroni, Alessandra Bandera, Massimo Galli, et al.
AIDS (London, England)
|
January 4, 2021
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis
Alessandra Cazzaniga, Roberta Scrimieri, Massimo Galli, et al.
Current Medicinal Chemistry
|
November 30, 2007
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors
Antonio Mastrolorenzo, Stefano Rusconi, Andrea Scozzafava, et al.
Journal of Anesthesia, Analgesia and Critical Care
|
June 29, 2023
Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome
Arianna Gatti, Paola Fassini, Antonino Mazzone, et al.
International Journal of Antimicrobial Agents
|
June 27, 2022
The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions
Stefano Rusconi, Maria M Santoro, Amedeo F Capetti, et al.
AIDS Patient Care and Stds
|
February 1, 2007
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation
Cristina Gervasoni, Ottavia Vigano, Erika Grinelli, et al.
Idcases
|
July 18, 2025
Early <i>Scedosporium apiospermium</i> infection of a soil-contaminated traumatic injury successfully treated with isavuconazole: A case report
Gabriele Pagani, Francesco Bassani, Paola Mirri, et al.
Journal of Medical Virology
|
May 20, 2014
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA)
Roberto Rossotti, Luigi Fonte, Genny Meini, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
December 20, 2015
Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy
Francesco Roberto Simonetti, Davide Ricaboni, Dario Cattaneo, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2004
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet
Stefano Rusconi, Alessio Innocenti, Daniela Vullo, et al.
Page
of 20
Search research articles
Search
Showing results (11-20 of 192) with videos related to
Sort By:
Page
of 20
AIDS Research and Human Retroviruses
|
October 13, 2005
Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol
Elisabetta Bulgheroni, Alessandra Bandera, Massimo Galli, et al.
AIDS (London, England)
|
January 4, 2021
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis
Alessandra Cazzaniga, Roberta Scrimieri, Massimo Galli, et al.
Current Medicinal Chemistry
|
November 30, 2007
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors
Antonio Mastrolorenzo, Stefano Rusconi, Andrea Scozzafava, et al.
Journal of Anesthesia, Analgesia and Critical Care
|
June 29, 2023
Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome
Arianna Gatti, Paola Fassini, Antonino Mazzone, et al.
International Journal of Antimicrobial Agents
|
June 27, 2022
The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions
Stefano Rusconi, Maria M Santoro, Amedeo F Capetti, et al.
AIDS Patient Care and Stds
|
February 1, 2007
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation
Cristina Gervasoni, Ottavia Vigano, Erika Grinelli, et al.
Idcases
|
July 18, 2025
Early <i>Scedosporium apiospermium</i> infection of a soil-contaminated traumatic injury successfully treated with isavuconazole: A case report
Gabriele Pagani, Francesco Bassani, Paola Mirri, et al.
Journal of Medical Virology
|
May 20, 2014
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA)
Roberto Rossotti, Luigi Fonte, Genny Meini, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
December 20, 2015
Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy
Francesco Roberto Simonetti, Davide Ricaboni, Dario Cattaneo, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2004
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet
Stefano Rusconi, Alessio Innocenti, Daniela Vullo, et al.
Page
of 20